ACP
BNTX icon

Ashfield Capital Partners’s BioNTech BNTX Stock Holding History

Ashfield Capital Partners’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,587
Closed -$2.32M – 231
2022
Q1 		$2.32M Sell
13,587
-595
-4% -$100K 0.15% 101
2021
Q4 		$3.66M Buy
14,182
+162
+1% +$44.4K 0.23% 80
2021
Q3 		$3.83M Buy
+14,020
New +$4.46M 0.27% 77

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Ashfield Capital Partners's BNTX Position: Q2 2022 in Review

Ashfield Capital Partners sold out of BioNTech (BNTX) in Q2 2022, closing a stake of 13,587 shares — an estimated $2.32M sold.

Ashfield Capital Partners first reported a position in BNTX in Q3 2021 and held it in 3 quarters. The position peaked at $3.83M in Q3 2021. 293 funds tracked by Wall St. Rank hold BNTX as of Q2 2022.

  • Ashfield Capital Partners reported no remaining BioNTech position as of Q2 2022 after selling out during the quarter.
  • Ashfield Capital Partners sold 13,587 BioNTech shares in Q2 2022, an estimated $2.32M.
  • Ashfield Capital Partners first reported a position in BioNTech in Q3 2021 and held it in 3 quarters.
  • Ashfield Capital Partners's BioNTech position peaked at $3.83M in Q3 2021.
  • 293 funds tracked by Wall St. Rank held BioNTech as of Q2 2022.

Based on Ashfield Capital Partners's 13F filing for Q2 2022, filed 29 Jul 2022.